CDXS vs. ANNX, TSVT, CGEN, ME, GLSI, GRTS, TLSI, FF, QURE, and CDT
Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Annexon (ANNX), 2seventy bio (TSVT), Compugen (CGEN), 23andMe (ME), Greenwich LifeSciences (GLSI), Gritstone bio (GRTS), TriSalus Life Sciences (TLSI), FutureFuel (FF), uniQure (QURE), and Conduit Pharmaceuticals (CDT).
Codexis (NASDAQ:CDXS) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
Codexis has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.
Codexis received 310 more outperform votes than Annexon when rated by MarketBeat users. However, 67.35% of users gave Annexon an outperform vote while only 61.14% of users gave Codexis an outperform vote.
Codexis currently has a consensus price target of $6.80, indicating a potential upside of 109.23%. Annexon has a consensus price target of $13.43, indicating a potential upside of 113.49%. Given Annexon's stronger consensus rating and higher probable upside, analysts plainly believe Annexon is more favorable than Codexis.
87.9% of Codexis shares are held by institutional investors. 6.3% of Codexis shares are held by insiders. Comparatively, 19.1% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Annexon had 6 more articles in the media than Codexis. MarketBeat recorded 7 mentions for Annexon and 1 mentions for Codexis. Codexis' average media sentiment score of 1.71 beat Annexon's score of 0.37 indicating that Codexis is being referred to more favorably in the media.
Annexon has a net margin of 0.00% compared to Codexis' net margin of -108.69%. Codexis' return on equity of -47.58% beat Annexon's return on equity.
Codexis has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Summary
Codexis beats Annexon on 10 of the 17 factors compared between the two stocks.
Get Codexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools